Skip to main content

Table 1 Clinical variables of the 105 hypertensive patients with or without arterial stiffness

From: Serum levels of sclerostin as a potential biomarker in central arterial stiffness among hypertensive patients

Characteristic

All participants

(n = 105)

Low AS group

(n = 69)

High AS group

(n = 36)

p value

Age (years)

64.51 ± 10.21

61.96 ± 10.01

69.42 ± 8.80

<  0.001*

Height (cm)

160.92 ± 8.47

161.55 ± 8.45

159.72 ± 8.50

0.296

Body weight (kg)

69.12 ± 12.31

68.71 ± 13.38

69.91 ± 10.10

0.639

Body mass index (kg/m2)

26.60 ± 3.61

26.16 ± 3.61

27.43 ± 3.50

0.088

cfPWV (m/s)

9.33 ± 2.76

7.78 ± 1.43

12.29 ± 2.23

<  0.001*

Systolic blood pressure (mmHg)

134.52 ± 17.85

131.41 ± 14.94

140.50 ± 21.39

0.013*

Diastolic blood pressure (mmHg)

73.72 ± 9.95

73.23 ± 9.96

74.67 ± 10.01

0.486

Total cholesterol (mg/dL)

174.51 ± 38.22

176.94 ± 36.85

169.86 ± 40.84

0.370

Triglyceride (mg/dL)

121.00 (93.50–172.00)

121.00 (94.00–174.00)

128.00 (89.50–173.50)

0.718

HDL-C (mg/dL)

45.62 ± 13.37

46.72 ± 13.86

43.50 ± 12.28

0.243

LDL-C (mg/dL)

103.25 ± 28.92

103.96 ± 26.20

101.89 ± 33.89

0.730

Fasting glucose (mg/dL)

114.00 (98.50–157.00)

116.00 (98.50–158.00)

115.00 (97.75–153.75)

0.893

Blood urea nitrogen (mg/dL)

16.91 ± 5.26

16.20 ± 4.74

18.28 ± 5.97

0.054

Creatinine (mg/dL)

1.10 ± 0.33

1.06 ± 0.28

1.19 ± 0.41

0.042*

eGFR (mL/min)

69.34 ± 20.51

72.86 ± 19.07

62.60 ± 21.72

0.014*

Total calcium (mg/dL)

9.17 ± 0.37

9.19 ± 0.37

9.14 ± 0.36

0.512

Phosphorus (mg/dL)

3.52 ± 0.51

3.56 ± 0.52

3.43 ± 0.49

0.219

iPTH (pg/mL)

50.81 ± 27.71

45.12 ± 22.04

61.72 ± 33.94

0.003*

Sclerostin (pmol/L)

69.34 ± 20.51

52.58 ± 21.66

74.77 ± 31.02

<  0.001*

Dickkopf-1 (pmol/L)

14.00 (6.06–28.82)

14.61 (5.94–30.23)

13.52 (6.02–25.51)

0.845

Female, n (%)

36 (34.3)

25 (36.2)

11 (30.6)

0.561

Diabetes mellitus, n (%)

46 (43.8)

25 (36.2)

21 (58.3)

0.030*

ACE inhibitor, n (%)

33 (31.4)

22 (31.9)

11 (30.6)

0.889

Angiotensin receptor blocker, n (%)

60 (57.1)

39 (56.5)

21 (58.3)

0.859

β-blocker, n (%)

62 (59.0)

37 (53.6)

25 (69.4)

0.118

Calcium channel blocker, n (%)

49 (46.7)

29 (42.0)

20 (55.6)

0.187

Statin, n (%)

64 (61.0)

46 (66.7)

18 (50.0)

0.097

Fibrate, n (%)

17 (16.2)

8 (11.6)

9 (25.0)

0.077

  1. Values for continuous variables are shown as mean ± standard deviation after analysis by Student’s t-test; variables not normally distributed are shown as median and interquartile range after analysis by the Mann-Whitney U test; values are presented as number (%) and analysis after analysis by the chi-square test
  2. AS arterial stiffness, cfPWV carotid–femoral pulse wave velocity, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, eGFR estimated glomerular filtration rate, iPTH intact parathyroid hormone, ACE angiotensin-converting enzyme
  3. Patients with cfPWV values > 10 m/s were assigned to the high AS group, whereas those with values ≤10 m/s constituted the low AS group
  4. *Values of p <  0.05 were considered statistically significant
Back to article page

BMC Cardiovascular Disorders

ISSN: 1471-2261

Contact us